HealthRX vs Hims & Hers
Two GLP-1 desks, one scoreboard. We put HealthRX and Hims & Hers head-to-head on the published Brief Score — the same six factors, scored the same way.
HealthRX
Hims & Hers
FDA warning letter, September 2025 — issued to Hims & Hers Health, Inc. dba Hims. See the FDA's warning letter database.
The verdict
HealthRX takes this head-to-head.
HealthRX scores 86 to 85 on our six-factor Brief Score — A LegitScript-certified, physician-supervised desk (healthrx.com) whose real hook is breadth: injectable and a rare oral GLP tablet, on both molecules, with transparent no-insurance monthly pricing.
That doesn't make Hims & Hers a bad call — it's best for readers who want a familiar, app-driven consumer brand and nationwide access. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| HealthRX | Hims & Hers | |
|---|---|---|
| Brief Score | 86/100 (B) | 85/100 (B) |
| Semaglutide | $190/mo month-to-month ($99 first month, renews at $165) · $99/mo on a 12-month prepay ($1,188) | $199/mo |
| Tirzepatide | $239/mo month-to-month ($149 first month, renews at $214) · $179/mo on a 12-month prepay ($2,148) | Not disclosed |
| Coverage | Not publicly listed | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| On the tracker | Stableprice stable | Risingprice rising |
HealthRX: Company-stated tiers held flat this cycle; the LegitScript badge and a rare oral GLP tablet are the draw, but some tiers are self-reported rather than checkout-verified.
Hims & Hers: App-first reach is nationwide, but compounded supply has drawn industry-wide scrutiny.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.